Further exploration of N-4 substituents on the piperazine ring of the hybrid template 5/ 7-{[2-(4-Aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol and its analog: development of an exceptionally potent agonist for D2 & D3 receptors

被引:0
作者
Dutta, Aloke K. [1 ]
Das, Banibrata [1 ]
Lote, Asawari [1 ]
Antonio, Tamara [2 ]
Reith, Maarten [2 ]
机构
[1] Wayne State Univ, Dept Pharmaceut Sci, Detroit, MI 48202 USA
[2] NYU, Dept Psychiat, New York, NY 10016 USA
关键词
Dopamine receptors; D-2; receptor; D-3; Agonist; Structure activity relationship study; CONSERVED SERINE RESIDUES; IN-VIVO ACTIVITY; HIGH-AFFINITY; DOPAMINE-RECEPTORS; D2/D3; AGONIST; D3; CLONING; LIGANDS; DISCOVERY; NEURONS;
D O I
10.1007/s00044-024-03291-3
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this manuscript we report a structure-activity relationship (SAR) study of analogs of 5/ 7-{[2-(4-Aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol. Our study is focused on introduction of various bioisoteric and aromatic substitutions on the piperazine ring of the hybrid template to further probe into the accessory binding domains on dopamine D-2/D-3 receptors. Specifically, the goal behind this study is to delineate the nature of the binding pockets for such substitutions on the piperazine ring to determine their influence on binding affinity (Ki), as measured with tritiated spiperone and HEK-293 cells expressing either D-2 or D-3 receptors. Functional activity of selected compounds was assessed with the GTP gamma S binding assay. Our data indicates that various N-substitution with substituted and unsubstituted benzene sulfonyl group produced varied affinity and potency for D-2/D-3. Compound D-660 produced highest selectivity for the D-3 receptor in the binding assay. In general, presence of hydroxyl group improved overall activity for both D-2/D-3 receptors. One such compound D-668 produced exceptional potencies for both the receptors. Overall, our results suggest that binding to the sites removed from the orthosteric binding sites contribute significantly to enhance functional potencies of ligands.
引用
收藏
页码:2420 / 2430
页数:11
相关论文
共 38 条
  • [1] Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: Identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity
    Biswas, Swati
    Hazeldine, Stuart
    Ghosh, Balaram
    Parrington, Ingrid
    Kuzhikandathil, Eldo
    Reith, Maarten E. A.
    Dutta, Aloke K.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (10) : 3005 - 3019
  • [2] Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: Identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action
    Biswas, Swati
    Zhang, Suhong
    Fernandez, Fernando
    Ghosh, Balaram
    Zhen, Juan
    Kuzhikandathil, Eldo
    Reith, Maarten E. A.
    Dutta, Aloke K.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (01) : 101 - 117
  • [3] The structural evolution of dopamine D3 receptor ligands:: Structure-activity relationships and selected neuropharmacological aspects
    Boeckler, Frank
    Gmeiner, Peter
    [J]. PHARMACOLOGY & THERAPEUTICS, 2006, 112 (01) : 281 - 333
  • [4] A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo
    Das, Banibrata
    Rajagopalan, Subramanian
    Joshi, Gnanada S.
    Xu, Liping
    Luo, Dan
    Andersen, Julie K.
    Todi, Sokol V.
    Dutta, Aloke K.
    [J]. NEUROPHARMACOLOGY, 2017, 123 : 88 - 99
  • [5] Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease
    Das, Banibrata
    Vedachalam, Seenuvasan
    Luo, Dan
    Antonio, Tamara
    Reith, Maarten E. A.
    Dutta, Aloke K.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (23) : 9179 - 9195
  • [6] Dopamine D3 Agonists in the Treatment of Parkinson's Disease
    Das, Banibrata
    Modi, Gyan
    Dutta, Aloke
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2015, 15 (10) : 908 - 926
  • [7] Synthesis and biological characterization of novel hybrid 7-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors
    Dutta, AK
    Venkataraman, SK
    Fei, XS
    Kolhatkar, R
    Zhang, SJ
    Reith, MEA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (16) : 4361 - 4373
  • [8] D-685 Reverses Motor Deficits and Reduces Accumulation of Human α-Synuclein Protein in Two Different Parkinson's Disease Animal Models
    Dutta, Aloke K.
    Armstrong, Christopher
    Luo, Dan
    Das, Banibrata
    Spencer, Brian
    Rissman, Robert A.
    [J]. ACS CHEMICAL NEUROSCIENCE, 2023, : 885 - 896
  • [9] Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines.: Implications for the binding mode of heterocyclic dopamine D3 receptor agonists
    Elsner, J
    Boeckler, F
    Heinemann, FW
    Hübner, H
    Gmeiner, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (18) : 5771 - 5779
  • [10] Dopamine receptors - physiological understanding to therapeutic intervention potential
    Emilien, G
    Maloteaux, JM
    Geurts, M
    Hoogenberg, K
    Cragg, S
    [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 84 (02) : 133 - 156